COSCIENS Biopharma Inc.
CSCIF
$2.09
-$0.16-7.27%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -46.84% | -20.74% | 17.63% | -27.08% | 20.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -46.84% | -20.74% | 17.63% | -27.08% | 20.10% |
| Cost of Revenue | -9.11% | 2.63% | 16.93% | -8.33% | -68.47% |
| Gross Profit | -70.28% | -43.05% | 18.93% | -51.00% | 261.08% |
| SG&A Expenses | 279.63% | -29.78% | -13.37% | 76.69% | -121.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.70% | -46.82% | -16.25% | 32.19% | 167.61% |
| Operating Income | -607.01% | 56.91% | 37.34% | -99.39% | -93.26% |
| Income Before Tax | 61.53% | 69.00% | -42.41% | -101.60% | -186.28% |
| Income Tax Expenses | -99.08% | -- | 100.21% | -- | 222.26% |
| Earnings from Continuing Operations | 67.57% | 68.39% | -89.94% | -160.89% | -190.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 67.57% | 68.39% | -89.94% | -160.89% | -190.57% |
| EBIT | -607.01% | 56.91% | 37.34% | -99.39% | -93.26% |
| EBITDA | -957.69% | 58.76% | 38.84% | -126.25% | -93.51% |
| EPS Basic | 36.09% | 69.10% | -32.82% | -53.30% | -208.06% |
| Normalized Basic EPS | -448.08% | 64.98% | 0.41% | -18.44% | -77.58% |
| EPS Diluted | 36.09% | 69.10% | -32.82% | -53.30% | -208.15% |
| Normalized Diluted EPS | -448.08% | 64.98% | 0.41% | -18.44% | -77.58% |
| Average Basic Shares Outstanding | 103.00% | 2.28% | 42.99% | 70.20% | -16.19% |
| Average Diluted Shares Outstanding | 103.00% | 2.28% | 42.99% | 70.20% | -16.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |